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INTRODUCTION 
Due to their unusual ability to cleave and degrade a variety of ECM components, including triple-helical type IV 
collagen, two members of the family of matrix metalloproteinases (MMPs), MMP-2 and MMP-9, are thought to 
play critical roles during tumor invasion and metastasis. The proteolytic activity of mature MMPs is modulated 
by a group of specific inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). Excessive ECM 
degradation observed during tumor invasion and metastasis frequently correlates with an excess of active MMPs. 
Therefore, adding exogenous inhibitors was contemplated for anticancer therapy. Indeed, synthetic MMP 
inhibitors have been demonstrated to reduce tumor invasion and metastasis in several in vitro and in vivo 
models.1
Here, we show that some of these synthetic inhibitors paradoxically enhance the production of MMP-9 even as 
they inhibit the activity of others (MMP-2, MT1-MMP). 
 
RESULTS 
GI Reduced the Invasion of HT1080 Cells through Type IV Collagen 
We first demonstrated, using Transwell chambers coated with type IV collagen,2 that GI129471 (GI, 1 µM), an 
hydroxamate-based inhibitor,3 reduces HT1080 cell invasion up to about 20% of that of the vehicle-treated cells 
(data not shown). In contrast, neither the ability of the cells to migrate through uncoated filters nor their 
metabolism were affected by GI, indicating that the inhibition of HT1080 invasion was most probably mediated 
through reduced proteolytic activity. Gelatin zymography of conditioned media from the chemoinvasion assays 
revealed that HT1080 essentially secreted pro-MMP-2 and pro-MMP-9. In addition, two activated forms of 
MMP-2 and a 120-kDa gelatinase activity (corresponding to a complex between TIMP-1 and the pro-MMP-9) 
were also detected (FIG. 1). Upon treatment with GI, the MMP-2 activated forms were undetectable, indicating 
the inhibition of MT1-MMP activity. Unexpectedly, the levels of both pro-MMP-9 and 120-kDa complex were 
strongly increased. 
GI Stimulated MMP-9 Production by HT1080 Cells 
To further investigate the effect of GI on MMP-9 secretion, HT 1080 cells were treated for 48 hours with graded 
GI concentrations (0-1 µM). GI dose-dependently stimulated the secretion of pro-MMP-9 with a maximal 6.6-
fold stimulation at 1 µM (FIG. 1). In contrast, pro-MMP-2 processing was dose-dependently inhibited. On the 
other hand, neither rTIMP-1 nor rTIMP-2 (0.01-1 µM), the physiological MMP inhibitors, significantly 
modulated MMP-9 secretion (data not shown). 
Using quantitative RT-PCR, we have shown that GI (0-1 µM) treatment increases the MMP-9 mRNA level (FIG. 
2). The effect of GI was dose dependent up to the concentration of 1 µM. Northern blot analysis showed that GI 
does not alter MMP- 1, MMP-2, MT1-MMP, TIMP-1, or TIMP-2 mRNA levels (data not shown). 
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FIGURE 1: GI modulates MMP-9 secretion in HT1080 cells. Conditioned media obtained from cells cultured 
for 48 hr with GI (0-1 µM) were analyzed by gelatin zymography. The relative gelatinolytic activity 
corresponding to MMP-9 was evaluated by scanning densitometry. A value of 1 was arbitrarily given to the 
control condition. Relative stimulation (fold) of MMP-9 secretion is shown. 
 
 
FIGURE 2: GI increases MMP-9 mRNA levels in HT1080 cells. MMP-9 mRNA levels were quantified by 
quantitative RT-PCR and densitometric analysis of autoradiographies of the gels. All results were corrected by 
densitometric data obtained for the 28S rRNA. A value of 1 was arbitrarily attributed to the relative level of 
MMP-9 mRNA measured in control condition. 
 
GI Stimules the Transcriptional Activity of the MMP-9 Promoter 
In order to assess the effect of GI on MMP-9 transcription, HT1080 cells were transiently transfected with 
pNA7.8 reporter vector. This construct was made up of the murine MMP-9 promoter (-7745 to +1 bp) linked to 
the β-galactosidase reporter gene. In the presence of GI, a fourfold stimulation of β-galactosidase activity was 
noted after 48 hours (data not shown). These data clearly demonstrated that the GI-stimulated MMP-9 synthesis 
was mediated through an enhanced transcription of the MMP-9 gene. 
CONCLUSIONS 
Our findings clearly demonstrate that GI129471, a broad-spectrum hydroxamate-based MMP inhibitor, could, in 
addition to its classical inhibitory activities, specifically upregulate both transcription and synthesis of pro-
MMP-9. Our data thus emphasize the need to carefully investigate the potential side effects of such unspecific 
broad-spectrum MMP inhibitors. 
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